Charles S. Grob, M.D., is currently Professor of Psychiatry and Pediatrics at the UCLA School of Medicine and the Director of the Division of Child and Adolescent Psychiatry at the Harbor-UCLA Medical Center. He has a long-standing interest in the history of psychiatric research with hallucinogens, and has published in the psychiatric literature and has given talks at professional meetings in this area. Dr. Grob received the first FDA approval to carry out human research with 3,4-methylenedioxymethamphetamine (MDMA). He collaborated with Drs. Dennis McKenna and Jace Callaway on a project to study the biochemical, physiological, and psychological parameters of long-term ayahuasca use in Brazil. In collaboration with Dr. Marlene Dobkin de Rios, he has examined the sociocultural context within which the use of these compounds occurs. In 2004 Dr. Grob initiated an FDA approved research investigation examining the effects of psilocybin in advanced-stage cancer patients with severe anxiety, which was completed in 2008. He is also the editor of Hallucinogens: A Reader, and the co-editor with Dr. Roger Walsh of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics.
Psychedelic Research Resurrected:
The Contributions of Stanislav Grof
This presentation will discuss Stan Grof's impact on the resurgent field of psychedelic research, particularly in regard to the development of the psilocybin treatment of advanced-cancer anxiety studies that were conducted in the early 2000s. After decades of repression, we are on the threshold of demonstrating that the field Stan and his colleagues courageously started many years ago still has remarkable contributions to make.